{
  "model": "chatgpt-gpt-5.3-codex",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "workspacePath": "workspaces/chatgpt-gpt-5-3-codex-tumor-vaccine-ici-run-1",
  "success": true,
  "schemaPass": true,
  "toolTracePass": true,
  "graderPass": true,
  "durationMs": 74712,
  "agentCostUsd": 0.0641325,
  "graderCostUsd": 0.014581,
  "totalCostUsd": 0.07871349999999999,
  "agentUsage": {
    "promptTokens": 17274,
    "cachedTokens": 0,
    "responseTokens": 3518,
    "thinkingTokens": 736,
    "totalTokens": 21528
  },
  "graderUsage": {
    "promptTokens": 4148,
    "cachedTokens": 0,
    "responseTokens": 177,
    "thinkingTokens": 346,
    "totalTokens": 4671
  },
  "totalUsage": {
    "promptTokens": 21422,
    "cachedTokens": 0,
    "responseTokens": 3695,
    "thinkingTokens": 1082,
    "totalTokens": 26199
  },
  "modelVersions": [
    "chatgpt-gpt-5.3-codex"
  ],
  "agentFinalText": "- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral mRNA vaccination induce an interferon-driven tumor state that improves response to anti-PD-L1 checkpoint blockade?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-combo\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Pooled repeat experiments testing intratumoral mRNA vaccine plus anti-PD-L1 in murine tumor models to assess tumor-control efficacy.\"\n    },\n    {\n      \"id\": \"mouse-matched-controls\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Matched control groups included vaccine-only, ICI-only, and vehicle conditions to test whether sensitization required the specific combination.\"\n    },\n    {\n      \"id\": \"human-retrospective-metastatic\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients total\",\n      \"description\": \"Metastatic patients treated with ICI were compared by prior SARS-CoV-2 mRNA vaccination status in a non-randomized retrospective analysis.\"\n    },\n    {\n      \"id\": \"human-vaccinated-subgroup\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective ICI-treated metastatic cohort with prior SARS-CoV-2 mRNA vaccination, used for survival comparison.\"\n    },\n    {\n      \"id\": \"human-unvaccinated-subgroup\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subset of the retrospective ICI-treated metastatic cohort without prior SARS-CoV-2 mRNA vaccination, serving as comparator.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized, so residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n  ]\n}"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Intratumoral mRNA vaccination was associated with broader antigen display.\",\n      \"evidence_line_refs\": [\n        \"L28\"\n      ]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"The MHC-I-presented peptide landscape expanded substantially after vaccination.\",\n      \"evidence_line_refs\": [\n        \"L29\"\n      ]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated patients in the retrospective ICI-treated cohort showed improved survival versus unvaccinated patients.\",\n      \"evidence_line_refs\": [\n        \"L30\"\n      ]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Tumors showed marked induction of type I interferon response after mRNA vaccination.\",\n      \"evidence_line_refs\": [\n        \"L31\"\n      ]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint-axis target expression increased in tumor tissue after vaccination.\",\n      \"evidence_line_refs\": [\n        \"L32\"\n      ]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Combination therapy was associated with increased intratumoral CD8+ T-cell infiltration.\",\n      \"evidence_line_refs\": [\n        \"L33\"\n      ]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination broadened tumor antigen presentation, including peptides displayed through MHC-I.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Type I interferon signaling is a key mechanistic requirement for the observed sensitization to checkpoint blockade.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors, limiting certainty about human mechanistic dependence.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"mRNA vaccination increased checkpoint relevance and immune infiltration, supporting combination with anti-PD-L1 therapy.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"| PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\",\n          \"line_ref\": \"L32\"\n        },\n        {\n          \"quote\": \"| Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\",\n          \"line_ref\": \"L33\"\n        },\n        {\n          \"quote\": \"4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        }\n      ],\n      \"caveat\": \"Vaccine-only and ICI-only controls showed limited standalone benefit in low-immunogenic settings, so benefit depends on context.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"In the retrospective metastatic cohort, prior SARS-CoV-2 mRNA vaccination was associated with better survival during ICI treatment.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\",\n          \"line_ref\": \"L15\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized, with variable vaccination timing and heterogeneous tumor/treatment backgrounds.\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"headline\": \"mRNA vaccination inside tumors may help some cancers respond better to checkpoint immunotherapy\",\n  \"plain_language_summary\": \"This study tested whether injecting an mRNA vaccine directly into tumors can make resistant cancers more visible to the immune system before giving checkpoint blockade treatment. In mouse models, the combination of intratumoral mRNA vaccine plus anti-PD-L1 was linked to stronger immune-related changes, including higher interferon signaling, broader antigen display on MHC-I, increased PD-L1 expression, and more CD8+ T-cell infiltration. The paper also reports a retrospective analysis of 130 metastatic patients treated with immune checkpoint inhibitors, where previously vaccinated patients had better survival (p=0.01). Together, these findings support a plausible biological strategy for improving immunotherapy response, but they do not yet prove causation in patients.\",\n  \"what_is_new\": [\n    \"The work links intratumoral mRNA vaccination to broader tumor peptide presentation, including expansion of the MHC-I peptidome.\",\n    \"Mechanistic tests suggest type I interferon signaling is required, because anti-IFNAR1 blockade removed the sensitization effect.\",\n    \"The study combines preclinical mechanism data with a human retrospective survival signal in ICI-treated metastatic patients.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The patient analysis was retrospective and non-randomized, so hidden differences between groups could explain part of the outcome gap.\",\n    \"Vaccination timing relative to checkpoint therapy varied across patients, making treatment effects harder to isolate cleanly.\",\n    \"Tumor-type and prior-treatment heterogeneity limit direct causal interpretation and can reduce generalizability.\",\n    \"Not all mechanistic signals were equally strong across every tested model system.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A cancer therapy that removes immune brakes, helping T cells attack tumors; anti-PD-L1 is one example.\"\n    },\n    {\n      \"term\": \"Intratumoral\",\n      \"definition\": \"Delivered directly into a tumor rather than into the bloodstream or muscle, aiming for strong local immune effects.\"\n    },\n    {\n      \"term\": \"MHC-I peptidome\",\n      \"definition\": \"The collection of small protein fragments displayed by MHC-I molecules on cells, which helps CD8+ T cells recognize targets.\"\n    },\n    {\n      \"term\": \"Type I interferon signaling\",\n      \"definition\": \"An innate immune pathway that can boost antiviral-like responses and enhance antigen processing and presentation.\"\n    },\n    {\n      \"term\": \"Retrospective cohort\",\n      \"definition\": \"A study design that analyzes existing patient data after treatment occurred, useful for signals but weaker for proving causation.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will prospective randomized trials confirm that intratumoral mRNA vaccination directly improves ICI outcomes in patients?\",\n    \"Which tumor types and baseline immune states are most likely to benefit from this sensitization strategy?\",\n    \"What vaccination timing and dosing schedule relative to checkpoint blockade gives the best risk-benefit profile?\"\n  ]\n}"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 24,
    "failedCalls": 0,
    "toolsUsed": [
      "list_directory",
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-12T14:34:20.818Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": ".",
        "timestamp": "2026-02-12T14:34:23.538Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "schemas",
        "timestamp": "2026-02-12T14:34:23.539Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-12T14:34:23.539Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-12T14:34:26.230Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-12T14:34:26.231Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-12T14:34:26.231Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-12T14:34:26.231Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-12T14:35:22.424Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-12T14:35:22.424Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-12T14:35:22.424Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-12T14:35:22.424Z"
      }
    ]
  },
  "grader": {
    "model": "gpt-5.2",
    "value": {
      "verdict": "pass",
      "scores": {
        "faithfulness": 5,
        "coverage": 5,
        "usefulness": 5
      },
      "critical_issues": [],
      "summary": "All provided JSON outputs are consistent with the numbered report lines and do not introduce fabricated quantitative results. Cohort sizes (78/84 mice; 130 total humans with 43 vaccinated/87 unvaccinated) match L19–L23. Quantitative findings faithfully reproduce the reported values and p-value (L28–L33) with valid line references. Controls/null results and the mechanistic dependence on type I interferon signaling (anti-IFNAR1 abrogation) are correctly included (L36–L40). Major caveats about the "
    }
  }
}
